![Prakash Raman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 82 433 $ in data 31/05/2026
Prakash Raman is currently Chief Executive Officer at Indupro since 2024, Chief Executive Officer & Director at InduPro, Inc. since 2024, Independent Director at Olema Pharmaceuticals, Inc. starting 2026, and Independent Director at Black Diamond Therapeutics, Inc. since 2024.
Former roles include Co-Chief Executive Officer & Director at KSQ Therapeutics, Inc., President, Chief Executive Officer & Director at Ribon Therapeutics, Inc., Director at NAYA Therapeutics, Inc., Vice President & Global Head of NIBR Business Development at Novartis Institutes for Biomedical Research, Inc. from 2012 to 2019, and Head of Project Management at AstraZeneca PLC from 2011 to 2012.
Education includes a doctorate from the University of Wisconsin-Madison and undergraduate and graduate degrees from the Indian Institute of Technology Bombay.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 27/04/2026 | 37.132 ( 0,06% ) | 82 433 $ | 31/05/2026 | |
| 28/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 10/04/2024 |
| OLEMA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 28/04/2026 |
Indupro | Amministratore Delegato | 13/06/2024 |
InduPro, Inc.
 InduPro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Amministratore Delegato | 01/04/2024 |
| Società | Posizione | Fine |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/10/2019 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/11/2012 |
Ribon Therapeutics, Inc.
 Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Amministratore Delegato | - |
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Amministratore Delegato | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Indian Institute of Technology Bombay
 Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Health Technology |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Olema Pharmaceuticals, Inc.
 Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Indupro | |
InduPro, Inc.
InduPro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
